Pipelines

합성 신약 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-943 Opioid Receptor Kappa agonist No CNS related adverse events (affects PNS only) License-in from Cara Therapeutics in the US	Uremic pruritus
CKD-950 A3 Adenosine receptor agonist (A3AR agonist) License-in from Can-fite Biopharma in Israel	Hepatocellular carcinoma
CKD-951 A3 Adenosine receptor agonist (A3AR agonist) License-in from Can-fite Biopharma in Israel	Metabolic dysfunction-associated steatohepatits
CKD-508 CETP inhibitor	Dyslipidemia
CKD-510 HDAC6 inhibitor License-out to Norvatis in the Switzerland	Rare disease
CKD-512 A2aR antagonist	Cancer

바이오 의약품 진행 프로젝트 테이블
Indication		Research	Preclinical	Phase I	Phase II	Phase III
CKD-702 Bispecific antibody	Cancer
CKD-703 cMET-ADC	Cancer
CKD-971 IFN-alpha kinoid License-in from Neovacs in France	Lupus
Tedopi a novel T-cell epitope-based cancer vaccine icense-in from OSE Immunotherapeutics in France	HLA-A2+ non-small cell lung cancer
Pembrolizumab biosimilar Programmed death receptor-1 (PD-1)-blocking antibody License-in from Favorex in Singapore	14 cancers including melanoma